Markets
Citizens Upgrades Bicara Therapeutics Price Target: What CRC Data Means for BCAX Stock
Citizens has lifted its price target on Bicara Therapeutics following encouraging colorectal cancer trial data, injecting fresh momentum into BCAX. Here is what the catalyst means for the stock's near-term setup and longer-term investment case.